RedHill Biopharma (RDHL) Operating Expenses (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Operating Expenses data on file, last reported at $4.8 million in Q2 2023.

• Operating Expenses for Q2 2023 came in at $4.8 million, down 48.2% year-over-year; the trailing twelve-month figure through Dec 2024 was $4.8 million (down 75.21% YoY), and the FY2025 annual result was $8.2 million, up 16.03% from the prior year.
• Operating Expenses retreated to $4.8 million in Q2 2023 per RDHL's latest filing, from $6.9 million in the prior quarter.
• Over five years, Operating Expenses peaked at $20.6 million in Q2 2021 and troughed at $4.8 million in Q2 2023.
• A 5-year average of $10.0 million and a median of $9.2 million in 2020 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2021 and 2022: Operating Expenses soared 122.37% in 2021, then plunged 55.08% in 2022.
• A 5-year view of Operating Expenses shows it stood at $6.4 million in 2019, then surged by 112.48% to $13.6 million in 2020, then decreased by 8.43% to $12.5 million in 2021, then plunged by 38.78% to $7.6 million in 2022, then plunged by 37.31% to $4.8 million in 2023.
• Business Quant data shows RDHL's Operating Expenses at $4.8 million in Q2 2023, $6.9 million in Q1 2023, and $7.6 million in Q4 2022.